A recent review of treatment options and evidence-based guidelines by Grothey et al. noted that current NCCN guidelines recommend combination chemotherapy as first-line in the treatment of patients with metastatic colorectal cancer, including those harbouring the BRAF mutation [36]. The gene discussed is BRAF; the disease is metastatic colorectal cancer.